Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Merck KGaA to present avelumab data at ASCO 2015

Pfizer and Merck KGaA to present avelumab data at ASCO 2015

14th May 2015

Pfizer and Merck KGaA have confirmed that they will be sharing insights into one of their collaborative drug development programmes at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.

The companies will present early data on the investigational immuno-oncology therapy avelumab across multiple tumour types, marking the first time they have made a joint presentation at a major global conference since the formation of the partnership.

Experts will discuss the performance of the fully human anti-PD-L1 IgG1 monoclonal antibody in an oral presentation on ovarian cancer, as well as posters on gastric cancer, non-small cell lung cancer and several other studies in a range of patient populations.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs and chief medical officer for Pfizer Oncology, said: "The field of immuno-oncology offers a vast opportunity for the development of new therapies that have the potential to change the way cancer is treated."

Merck KGaA and Pfizer announced their strategic alliance to jointly develop and commercialise avelumab back in November 2014.ADNFCR-8000103-ID-801787346-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.